Skip to main content

Table 1 Patient characteristics

From: Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking

Total patients (n = 39)
Age   
  ≤ 69 years 20 (51.3%)
  > 69 years 19 (48.7%)
Tumor stage   
  cT1 12 (30.8%)
  cT2 5 (12.8%)
  cT3a 13 (33.4%)
  cT3b 7 (17.9%)
  cT4 2 (5.1%)
Gleason score   
  2–6 20 (51.3%)
  7 13 (33.3%)
  8–10 6 (15.4%)
Pre-treatment PSA   
  ≤ 10 ng/mL 20 (51.3%)
  >10 ng/mL 19 (48.7%)
Risk group   
  Low 7 (17.9%)
  Intermediate 8 (20.5%)
  High 24 (61.6%)
Hormonal therapy   
  no 10 (25.6%)
  yes 29 (74.4%)
Median FU months† (range)   29 (22–40)
  1. Abbreviations: PSA = prostate- specific antigen; FU = follow-up;
  2. †period after completion of treatment.